NCT07730021

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-09-02Est. Completion: 2030-02-28

Enrollment target: 392 participants

Locations

START New York, Lake Success, New York, United States
NEXT Virginia, Fairfax, Virginia, United States
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan

Contact

Astellas Pharma Global Development, Inc.Astellas.registration@astellas.com 800-888-7704

Other microbiome trials you might be interested in

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerPhase 2Recruiting

Recurrent Breast CarcinomaStage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7

This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treat…

Mobile, United StatesEst. completion Nov 6, 2020

View Trial →

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Phase 3Recruiting

Non-small Cell Lung Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.